Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited

Anesthesia and Analgesia

Volumn 114, Issue 2, 2012, Pages 275-285

  Wolberg, Alisa S ^a   Aleman, Maria M ^a   Leiderman, Karin ^a   Machlus, Kellie R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; FIBRIN; FIBRINOGEN; INTERLEUKIN 1; KRUPPEL LIKE FACTOR; P SELECTIN GLYCOPROTEIN LIGAND 1; PLASMA PROTEIN; PROTHROMBIN; THROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ARTERY THROMBOSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD FLOW; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CELL ADHESION; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENE MUTATION; HEART MUSCLE CELL; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; LEUKOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SHEAR FLOW; SHEAR RATE; SHEAR STRESS; SUBENDOTHELIUM; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; ENDOTHELIAL CELLS; HEMODYNAMICS; HEMOSTASIS; HUMANS; LEUKOCYTES; THROMBOSIS;

EID: 84856223002     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31823a088c     Document Type: Review

References (139)

1. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011;123:933-44
2. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011;154:529-40
3. Schwartz NE, Albers GW. Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. Stroke 2010;41:1307-9
4. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991;253:909-12 (Pubitemid 21917236)
5. Lord ST. Fibrinogen and fibrin: Scaffold proteins in hemostasis. Curr Opin Hematol 2007;14:236-41 (Pubitemid 46597609)
6. Weisel JW. Structure of fibrin: Impact on clot stability. J Thromb Haemost 2007;5(Suppl 1):116-24 (Pubitemid 46958824)
7. Chernysh IN, Nagaswami C, Weisel JW. Visualization and identification of the structures formed during early stages of fibrin polymerization. Blood 2011;117:4609-14
8. Liu W, Jawerth LM, Sparks EA, Falvo MR, Hantgan RR, Superfine R, Lord ST, Guthold M. Fibrin fibers have extraordinary extensibillity and elasticity. Science 2006;313:634 (Pubitemid 44201134)
9. Ghosh K, Shetty S, Jijina F, Mohanty D. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia 2004;10:58-62 (Pubitemid 38195626)
10. White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RM, Norris RM. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 1989;320:817-21 (Pubitemid 19094700)
11. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
12. Popuri RK, Vedantham S. The role of thrombolysis in the clinical management of DVT. Arterio Thromb Vasc Biol 2011;31:479-84
13. Nair CH, Shah GA, Dhall DP. Effect of temperature, pH and ionic strength and composition on fibrin network structure and its development. Thromb Res 1986;42:809-16 (Pubitemid 16019838)
14. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008;112:2810-6
15. Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994;75:521-38 (Pubitemid 24267336)
16. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999;77:2813-26 (Pubitemid 29519524)
17. Glover CJ, McIntire LV, Brown CH 3rd, Natelson EA. Rheological properties of fibrin clots. Effects of fibrinogen concentration, factor XIII deficiency, and factor XIII inhibition. J Lab Clin Med 1975;86:644-56
18. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011;117:4953-63
19. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor-Xiii concentrations. Blood 1988;71:1361-5
20. Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 2008;6:161-80
21. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: Dynamic and structural approaches by confocal microscopy. Arterio Thromb Vasc Biol 2000;20:1354-61 (Pubitemid 30262939)
22. Carr ME Jr., Alving BM. Effect of fibrin structure on plasminmediated dissolution of plasma clots. Blood Coag Fibrinol 1995;6:567-73
23. Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alphaantiplasmin cross-linking. Blood 2011;117:6371-4
24. Bagot CN, Arya R. Virchow and his triad: A question of attribution. Br J Haematol 2008;143:180-90
25. Virchow R. Gesammalte abhandlungen zur wissenschaftlichen medtzin. Frankfurt: Medinger Sohn & Co., 1856:219-732
26. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703
27. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-62 (Pubitemid 30646484)
28. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001;21:731-8 (Pubitemid 32448761)
29. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5 (Pubitemid 14059351)
30. Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002;22:1042-5 (Pubitemid 34655237)
31. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg- Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant metaanalysis JAMA 2005;294:1799-809 (Pubitemid 41434626)
32. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003;1:2677-8
33. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991;83:836-44
34. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-6
35. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study group. Fragmin during instability in coronary artery disease. Circulation 1997;96:4204-10 (Pubitemid 28007445)
36. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-3 (Pubitemid 12235040)
37. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996;16:742-8
38. Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey. Christmas disease: A condition previously mistaken for haemophilia. BMJ 1952;2:1378-82
39. Macfarlane RG, Biggs R. A thrombin generation test: The application in haemophilia and thrombocytopenia. J Clin Pathol 1953;6:3-8
40. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007;27:683-9
41. Butenas S, van't Veer C, Cawthern K, Brummel KE, Mann KG. Models of blood coagulation. Blood Coag Fibrinol 2000;11(Suppl 1):S9-13 (Pubitemid 30368695)
42. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa enhances clot stability in a model of hemophilia B. Brit J Haematol 2005;131:645-55 (Pubitemid 43899632)
43. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005;93:475-80 (Pubitemid 40392535)
44. Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Beguin S, Hemker HC. The thrombogram in rare inherited coagulation disorders: Its relation to clinical bleeding. Thromb Haemost 2002;88:576-82 (Pubitemid 35173997)
45. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006;296:397-402 (Pubitemid 44127523)
46. Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, Finn JD, Spiezia L, Radu C, Arruda VR. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009;361:1671-5
47. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7 (Pubitemid 24144355)
48. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4
49. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study group. Fragmin during instability in coronary artery disease. N Engl J Med 2000;343:1139-47
50. Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, Horstman LL, Soriano AO, Zambrano JP, Ahn YS. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005;45:1467-71 (Pubitemid 40615620)
51. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010;116:113-21
52. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997;90:204-8 (Pubitemid 27276563)
53. Bark DL Jr., Ku DN. Wall shear over high degree stenoses pertinent to atherothrombosis. J Biomech 2010;43:2970-7
54. Roosendaal G, Lafeber FP. Blood-induced joint damage in hemophilia. Semin Thromb Hemost 2003;29:37-42 (Pubitemid 36250262)
55. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003;361:1801-9
56. Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, Forsyth A, Geraghty S, Hoots K, Abshire T, Curtis R, Forsberg A, Huszti H, Wagner M, White GC 2nd. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004;103:2467-73 (Pubitemid 38392995)
57. Bettigole RE, Hampton JW, Bird RM. Abnormal plasma clots in hemophilia. Thromb Diath Haemorrh 1964;12:331-7
58. He S, Blomback M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003;1:1215-9
59. Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG. Discordant fibrin formation in hemophilia. J Thromb Haemost 2009;7:825-32
60. Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007;137:158-65 (Pubitemid 46474712)
61. Kyrle PA, Mannhalter C, Beguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterio Thromb Vasc Biol 1998;18:1287-91 (Pubitemid 28376186)
62. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood 1999;94:2169-78
63. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: A possible mechanism of the increased thrombotic risk. Blood 2003;101:3008-13 (Pubitemid 36857988)
64. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004;2:402-13 (Pubitemid 40185650)
65. Machlus KR, Colby EA, Wu JR, Koch GG, Key NS, Wolberg AS. Effect of tissue factor, thrombomodulin, and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost 2009;102:936-44
66. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004;103:2157-61 (Pubitemid 38326233)
67. Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Med Chem 2008;6: 206-11
68. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999;81:680-3 (Pubitemid 29216549)
69. Gulledge AA, Rezaee F, Verheijen JH, Lord ST. A novel transgenic mouse model of hyperfibrinogenemia. Thromb Haemost 2001;86:511-6 (Pubitemid 32746937)
70. Gulledge AA, McShea C, Schwartz T, Koch G, Lord ST. Effects of hyperfibrinogenemia on vasculature of C57BL/6 mice with and without atherogenic diet. Arterioscler Thromb Vasc Biol 2003;23:130-5 (Pubitemid 36091637)
71. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004;103:1728-34 (Pubitemid 38268965)
72. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004;92:459-66 (Pubitemid 39248002)
73. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost 2007;5:1403-8 (Pubitemid 46965368)
74. Ovanesov MV, Ananyeva NM, Panteleev MA, Ataullakhanov FI, Saenko EL. Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: Initiator cells do not regulate spatial growth rate. J Thromb Haemost 2005;3:321-31 (Pubitemid 41623621)
75. Campbell RA, Overmyer KA, Bagnell CR, Wolberg AS. Cellular procoagulant activities dictate clot structure and stability as a function of distance from the cell surface. Arterio Thromb Vasc Biol 2008;28:2247-54
76. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009;114:4886-96
77. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez- Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-9 (Pubitemid 27063034)
78. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999;99:1780-7 (Pubitemid 29181404)
79. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986;83:4533-7 (Pubitemid 16057083)
80. Herbert JM, Savi P, Laplace MC, Lale A. IL-4 inhibits LPS-, IL-1 beta- and TNF alpha-induced expression of tissue factor in endothelial cells and monocytes. FEBS Lett 1992;310:31-3
81. Atkinson BT, Jasuja R, Chen VM, Nandivada P, Furie B, Furie BC. Laser-induced endothelial cell activation supports fibrin formation. Blood 2010;116:4675-83
82. Brooks EG, Trotman W, Wadsworth MP, Taatjes DJ, Evans MF, Ittleman FP, Callas PW, Esmon CT, Bovill EG. Valves of the deep venous system: An overlooked risk factor. Blood 2009;114:1276-9
83. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation 2008;117:93-102 (Pubitemid 350301144)
84. Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: A systematic review and a meta-analysis. J Thromb Haemost 2010;8:891-7
85. Maroney SA, Cooley BC, Sood R, Weiler H, Mast AE. Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue specific fibrin deposition. J Thromb Haemost 2008;6:111-7
86. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011;31:15-26
87. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011;108:1284-97
88. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: An isolated defect in platelet procoagulant activity. J Biol Chem 1989;264:17049-57
89. Castaman G, Yu-Feng L, Rodeghiero F. A bleeding disorder characterised by isolated deficiency of platelet microvesicle generation. Lancet 1996;347:700-1 (Pubitemid 26076165)
90. Kanazawa S, Nomura S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S. Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer. Lung Cancer 2003;39:145-9 (Pubitemid 36173614)
91. Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J, Mackman N, Taubman MB. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008;6:1983-5
92. Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A, Mannucci PM. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 2011;31:165-72
93. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-83 (Pubitemid 37193612)
94. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009;7:1421-3
95. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009;15:6830-40
96. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585-98 (Pubitemid 36682554)
97. Gross PL, Furie BC, Merrill-Skoloff G, Chou J, Furie B. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol 2005;78:1318-26 (Pubitemid 41779238)
98. Ramacciotti E, Hawley AE, Farris DM, Ballard NE, Wrobleski SK, Myers DD Jr., Henke PK, Wakefield TW. Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost 2009;101: 748-54
99. Aleman MM, Gardiner C, Harrison P, Wolberg AS. Unique contributions of monocyte- and platelet-derived microparticles to thrombin generation and fibrin formation and stability. J Thromb Haem 2011;9:2251-61
100. Biro E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE, Sturk A, Nieuwland R. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003;1: 2561-8
101. Reinhardt C, von Bruhl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, Dlugai S, Hess S, Konrad I, Orschiedt L, Mackman N, Ruddock L, Massberg S, Englelmann B. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008;118:1110-22 (Pubitemid 351364618)
102. Wang JG, Williams JC, Davis BK, Jacobson K, Doerschuk CM, Ting JP, Mackman N. Monocytic microparticles activate endothelial cells in an IL-1(beta)-dependent manner. Blood 2011;118:2366-74
103. Wootton DM, Ku DN. Fluid mechanics of vascular systems, diseases, and thrombosis. Ann Rev Biomed Engl 1999;1: 299-329 (Pubitemid 129740014)
104. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 2005;85:9-23 (Pubitemid 40128037)
105. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011;91:327-87
106. Lin Z, Kumar A, SenBanerjee S, Staniszewski K, Parmar K, Vaughan DE, Gimbrone MA Jr., Balasubramanian V, Garcia- Cardena G, Jain MK. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 2005;96:e48-57
107. Dekker RJ, Boon RA, Rondaij MG, Kragt A, Volger OL, Elderkamp YW, Meijers JC, Voorberg J, Pannekoek H, Horrevoets AJ. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 2006;107:4354-63 (Pubitemid 43801361)
108. Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW, Gerzsten RE, Edelman ER, Jain MK. Kruppellike factor 4 regulates endothelial inflammation. J Biol Chem 2007;282:13769-79 (Pubitemid 47100499)
109. Bhattacharya R, Senbanerjee S, Lin Z, Mir S, Hamik A, Wang P, Mukherjee P, Mukhopadhyay D, Jain MK. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem 2005;280:28848-51 (Pubitemid 41161328)
110. Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, Kratz JR, Lin Z, Jain MK, Gimbrone MA Jr, Garcia- Cardena G. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest 2006;116:49-58 (Pubitemid 43121790)
111. Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M, Aime G, Ahn YS. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003;41:211-7 (Pubitemid 36204891)
112. Silverman MD, Samet MM, Lelkew PI. Pressure modulates tissue factor expression in human aortic and vena endothelial cells. J Vasc Res 1996;33:93
113. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Pressure enhances endothelin-1 release from cultured human endothelial cells. Hypertension 1995;25:449-52
114. Hathcock JJ. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol 2006;26:1729-37 (Pubitemid 44305325)
115. Siegel JM, Markou CP, Ku DN, Hanson SR. A scaling law for wall shear rate through an arterial stenosis. J Biomech Engl 1994;116:446-51 (Pubitemid 24376575)
116. Turitto Vt, Hall CL. Mechanical factors affecting hemostasis and thrombosis. Thromb Res 1998;92:S25-31 (Pubitemid 29012760)
117. Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med 2009;6:16-26
118. Yong AS, Pennings GJ, Chang M, Hamzah A, Chung T, Qi M, Brieger D, Behnia M, Krilis SA, Ng MK, Lowe HC, Kritharides L. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood 2011;117:11-20
119. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, Jackson SP. A shear gradientdependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009;15:665-73
120. Shen F, Kastrup CJ, Liu Y, Ismagilov RF. Threshold response of initiation of blood coagulation by tissue factor in patterned microfluidic capillaries is controlled by shear rate. Arterioscler Thromb Vasc Biol 2008;28:2035-41
121. Neeves KB, Illing DA, Diamond SL. Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow. Biophys J 2010;98:1344-52
122. Wielders SJ, Broers J, ten Cate H, Collins PW, Bevers EM, Lindhout T. Absence of platelet-dependent fibrin formation in a patient with Scott syndrome. Thromb Haemost 2009; 102:76-82
123. Campbell RA, Aleman MM, Gray LD, Falvo MR, Wolberg AS. Flow profoundly influences fibrin network structure: Implications for fibrin formation and clot stability in hemostasis. Thromb Haemost 2010;104:1281-4
124. Varju I, Sotonyi P, Machovich R, Szabo L, Tenekedjiev K, Silva MM, Longstaff C, Kolev K. Hindered dissolution of fibrin formed under mechanical stress. J Thromb Haemost 2011;9:979-86
125. Hechler B, Nonne C, Eckly A, Magnenat S, Rinckel JY, Denis CV, Freund M, Cazenave JP, Lanza F, Gachet C. Arterial thrombosis: Relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost 2010;8:173-84
126. Machlus KR, Lin F-C, Wolberg AS. Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood 2011;118:390-8
127. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin: I. An empirical study. J Biol Chem 1994;269:23357-66 (Pubitemid 24283329)
128. Jones KC, Mann KG. A model for the tissue factor pathway to thrombin: II. A mathematical simulation. J Biol Chem 1994;269:23367-73 (Pubitemid 24283330)
129. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002;277:18322-33 (Pubitemid 34952376)
130. Kuharsky AL, Fogelson AL. Surface-mediated control of blood coagulation: The role of binding site densities and platelet deposition. Biophys J 2001;80:1050-74 (Pubitemid 32182136)
131. Fogelson AL, Tania N. Coagulation under flow: The influence of flow-mediated transport on the initiation and inhibition of coagulation. Pathophysiol Haemost Thromb 2005;34:91-108
132. Diamond SL. Systems biology to predict blood function. J Thromb Haemost 2009;7(Suppl 1):177-80
133. Panteleev MA, Ananyeva NM, Ataullakhanov FI, Saenko EL. Mathematical models of blood coagulation and platelet adhesion: Clinical applications. Curr Pharm Des 2007;13:1457-67 (Pubitemid 46860868)
134. Xu Z, Kamocka M, Alber M, Rosen ED. Computational approaches to studying thrombus development. Arterioscler Thromb Vasc Biol 2011;31:500-5
135. Hathcock JJ, Nemerson Y. Platelet deposition inhibits tissue factor activity: In vitro clots are impermeable to factor Xa. Blood 2004;104:123-7 (Pubitemid 38879847)
136. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006;26:41-8 (Pubitemid 43732226)
137. Gailani D, Renne T. The intrinsic pathway of coagulation: A target for treating thromboembolic disease? J Thromb Haemost 2007;5:1106-12 (Pubitemid 46902107)
138. Xu Z, Chen N, Kamocka MM, Rosen ED, Alber M. A multiscale model of thrombus development. J R Soc Interface 2008;5:705-22 (Pubitemid 351882148)
139. Leiderman K, Fogelson AL. Grow with the flow: A spatial- temporal model of platelet deposition and blood coagulation under flow. Math Med Biol 2011;28:47-84